Chemistry:PRC200-SS
From HandWiki
Short description: Triple reuptake inhibitor investigated by the Mayo Clinic
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C20H21NO |
| Molar mass | 291.394 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1][2]
Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.
References
- ↑ "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics 327 (2): 573–83. November 2008. doi:10.1124/jpet.108.143610. PMID 18689611.
- ↑ "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures. http://technologies.ventures.mayoclinic.org/technologies/2011-044_triple-reuptake-inhibitors-for-the-treatment-of-depression.
- ↑ "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor". Toxicological Sciences 120 (2): 269–83. April 2011. doi:10.1093/toxsci/kfr013. PMID 21258088.
 |  |
